Johnson & Johnson says it is prepared to provide its just-approved monthly injectable schizophrenia drug Invega Sustenna for free or at a huge discount to payers if specified outcomes are not achieved, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia.
"We need to put our money where our mouth is," said Richard Blockinger, director of marketing at Janssen, during an interview at an Oct. 31 company meeting for physician experts in Las Vegas, Nev.
[Editor's note: Looking for strategies to optimize your drug's positioning and reimbursement? Register today for our Nov. 24 webinar.]
At the forum, held in advance of the U.S. Psychiatric and Mental Health Congress, J&J presented its vision of a multi-faceted "new treatment paradigm" in schizophrenia, rooted in long-acting injectable therapies, to about a dozen physician consultants.
J&J manufactures the only two long-acting atypical antipsychotics currently available on the U.S. market. Both drugs face a tough environment, including competition from short-acting generics. J&J's ambitious plan aims to change how people think about antipsychotics in hopes of winning market share, despite the LAT's higher cost. ...
This article preview is reprinted from "The Pink Sheet" - Nov. 17, 2009. To purchase this article online, or to register for a free trial, click here.
